NIBIB's goal is to accelerate research, translation, and commercialization of technologies that will provide solutions to the COVID-19 pandemic.

NIBIB is administering the RADx℠ Tech and Advanced Technology Platforms (ATP) programs. These programs are part of the NIH RADx℠ Initiative to increase testing capacity and accessibility for SARS-CoV-2, the virus that causes COVID. In addition, NIBIB is supporting other technology development, imaging approaches, and digital platforms to address the pandemic.

Rapid Acceleration of Diagnostics (RADx℠) Tech and ATP Programs

The RADx Tech and ATP programs are supporting late-stage development of innovative point-of-care, home-based tests, and clinical laboratory tests.

Summary data on proposals submitted to the RADx℠ Tech and ATP Programs.

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

COVID-19 Research across NIBIB

NIBIB’s Dr. Kaitlyn Sadtler is a study lead and Principal Investigator working with NIH colleagues to test people who were infected with SARS-CoV-2 and developed antibodies but did not develop symptoms. Read more about the study.

Learn how this collaborative network is using medical imaging and clinical data sciences to reveal unique features of COVID-19. Learn more about the project.


View videos about RADx Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

RADxSM Tech/ATP programmatic or technical inquiries:

All other RADxSM Tech/ATP Applicants:

SBIR/STTR Applicants:

All others:

Related News

March 1, 2021
diagnostic test in a box
An NIH-funded research team has launched a study to assess performance and usability of a smartphone app paired with the Quidel QuickVue At-Home COVID-19 Test, which received FDA emergency use authorization for use with a prescription.
February 18, 2021
While the progress toward widespread COVID-19 vaccination is encouraging, testing, masking, social distancing, contact tracing and isolation will continue to play a key role in limiting outbreaks and keeping schools and businesses open. Source: BENCH press
February 17, 2021
The final RADx portfolio of products to be developed and scaled includes a diversity of diagnostics from companies such as Illumina, Quidel, Fluidigm, and Mesa Biotech, and is likely to result in a near-term manufacturing boom in rapid antigen tests and over-the-counter home-use diagnostics. Source: genomeweb.
February 1, 2021
The DOD, in coordination with the Department of Health and Human Services, awarded $231.8 million to Ellume USA LLC to onshore production capacity of the Ellume COVID-19 Home Test for the United States. Read more at the Department of Defense website.
January 19, 2021
CT chest and coronavirus
The Medical Imaging and Data Resource Center (MIDRC), a collaboration of leading medical imaging organizations funded by NIBIB, has launched a repository of imaging data to facilitate medical imaging research on COVID-19.